Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan (NYSE: AGN.DL  ) , Arena Pharmaceuticals (NASDAQ: ARNA  ) , and Bristol-Myers Squibb (NYSE: BMY  ) . 

Allergan looking to "upsize" to fight takeover bid
It's no secret that Allergan has been attempting to avoid a takeover by Valeant Pharmaceuticals (NYSE: VRX  ) . And recent events such as a special meeting of Allergan shareholders to discuss Valeant's offer suggests that management may end up losing this fight before much longer. 

Even so, Allergan's CEO David Pyott isn't going down without a fight. In an interesting turn of events, Pyott announced yesterday that the company is looking at a "sizable" acquisition that could end Valeant's hostile takeover bid.

Although the details of Pyott's plan haven't been made public, Shire's (NASDAQ: SHPG  ) name popped up as a possible target. Shire is presently mired in its own acquisition talks with AbbVie that are starting to reach fever pitch. Overall, I think Allergan may be down to its last cards here and talk about acquiring a similarly sized company looks more like a Hail Mary than a viable strategy to avoid a takeover. 

Arena announces completion of increased Belviq sales force
Shares of Arena are up slightly in premarket this morning after announcing that its marketing partner Eisai has completed its planned increase of 200 additional sales reps for the duo's fat-fighting pill Belviq. This increase is part of a broader relaunch effort of the drug after it has repeatedly posted disappointing prescription and sales numbers, following its initial commercial launch last year.

With Orexigen Therapeutic's rival drug likely to reach the market later this year, Eisai's renewed marketing efforts are coming at a pivotal time in the drug's life cycle. Put simply, this may be the last major effort to push the drug as a treatment for chronic obesity, as it stands. If this effort fails to dramatically improve the drug's commercial performance, I think the companies will wait for a label expansion to be approved before using any more resources to try to increase sales. 

Bristol-Myers to submit nivolumab for regulatory approval as a melanoma treatment
Bristol-Myers announced this morning that its plans on filing a Biologics Licensing Application for its closely watched PD-1 inhibitor called nivolubmab in the third quarter, as a potential treatment for advanced melanoma that has previously been treated with Yervoy or a BRAF inhibitor regimen.. Bristol-Myers is also in the process of completing a rolling submission for the drug as a treatment for non-small cell lung cancer.

In its press release, Bristol-Myers proposed the trade name Opdivo, if nivolumab is granted approval. Bristol-Myers is also developing nivolumab as a potential treatment for renal cell carcinoma, head and neck cancer, glioblastoma and non-Hodgkin lymphoma. Shares are presently unchanged in response to this news. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3023793, ~/Articles/ArticleHandler.aspx, 8/29/2015 9:06:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AGN.DL $0.00 Down +0.00 +0.00%
Allergan, Inc. CAPS Rating: ****
ARNA $2.71 Up +0.06 +2.26%
Arena Pharmaceutic… CAPS Rating: **
BMY $60.61 Down -0.21 -0.35%
Bristol-Myers Squi… CAPS Rating: ****
SHPG $235.96 Up +3.00 +1.29%
Shire plc (ADR) CAPS Rating: ****
VRX $236.12 Up +1.22 +0.52%
Valeant Pharmaceut… CAPS Rating: ***